Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis

Table 3 Different treatment regimens with OS benefited from ICI-based therapy over chemotherapy in targeted patients

Regimen	Population	No. of studies	Test of association			Test of heterogeneity
Regimen	Population	No. of studies	HR	95% CI	P value	I²	P value
1st-Line	Aged < 65 years	3	0.79	0.68–0.91	0.001	0%	0.89
	Male	3	0.86	0.76–0.98	0.02	0%	0.95
	PS 1	3	0.84	0.73–0.98	0.02	0%	0.61
	gastric tumor	3	0.84	0.74–0.96	0.009	0%	0.90
	CPS ≥ 10	2	0.77	0.61–0.97	0.03	0%	0.37
≥ 2nd-Line	oesophagogastric junction tumor	2	0.71	0.53–0.95	0.02	28%	0.24
combined therapy	Aged < 65 years	2	0.77	0.65–0.92	0.004	0%	0.81
	Male	2	0.85	0.73–1.00	0.04	0%	0.84
	PS 1	2	0.80	0.67–0.96	0.01	0%	0.86
	gastric tumor	2	0.84	0.72–0.99	0.04	0%	0.67
monotherapy	CPS ≥ 10	2	0.67	0.51–0.89	0.005	0%	0.81

ISSN: 1471-2407